Holen Sie sich die Stockscreener-App
3.36
6.67%
0.21
Vorhandelsmarkt:
3.43
0.07
+2.08%
Schlusskurs vom Vortag:
$3.15
Offen:
$3.12
24-Stunden-Volumen:
2.60M
Relative Volume:
1.08
Marktkapitalisierung:
$281.28M
Einnahmen:
$32.31M
Nettoeinkommen (Verlust:
$-237.09M
KGV:
-1.1667
EPS:
-2.88
Netto-Cashflow:
$-219.11M
1W Leistung:
+22.18%
1M Leistung:
+51.35%
6M Leistung:
+150.75%
1J Leistung:
-35.51%
1-Tages-Spanne:
$3.0306
$3.42
1-Wochen-Bereich:
$2.66
$3.42
52-Wochen-Spanne:
$0.9101
$5.85
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Vergleichen Sie EDIT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
3.36 | 230.21M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
What analysts say about Editas Medicine Inc. stockMarket-leading growth rates - jammulinksnews.com
Is Editas Medicine Inc. a good long term investmentExceptional profit margins - Autocar Professional
Editas Medicine Inc. Stock Analysis and ForecastUnrivaled growth potential - jammulinksnews.com
There's Reason For Concern Over Editas Medicine, Inc.'s (NASDAQ:EDIT) Massive 42% Price Jump - simplywall.st
What drives Editas Medicine Inc. stock priceConsistent high-yield stocks - Autocar Professional
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Numerous Editas Medicine Insiders Sold Stock: Not A Positive Omen - simplywall.st
Crispr Genomic Cure Market in 2032: A Glimpse Into the Future - openPR.com
Editas Medicine (EDIT) Soars 7.69% on Positive Data - AInvest
Cathie Wood shells out $13.9 million for one high-stakes biotech stock - Yahoo Finance
Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data - MSN
Restore Health – Therapies that cureTelethon - Ricerca Malattie Genetiche Rare
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 3000E Index - MarketScreener
Top 10 CRISPR Stocks to Buy Now - Insider Monkey
Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? - The Motley Fool
2 Beaten-Down Stocks to Avoid - The Globe and Mail
Gene Editing Market Set to Witness Significant Growth by 2025-2032 | CRISPR Therapeutics, Editas Medicine - openPR.com
Gene editing stocks gain amid FDA's latest leadership change (EDIT:NASDAQ) - Seeking Alpha
Cancer Gene Therapy Market Set to Soar: Breakthrough - openPR.com
From Now to 2032: Unpacking the Genome Editing Market's - openPR.com
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - AOL.com
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
Analysts Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36 - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Position Trimmed by Bank of America Corp DE - MarketBeat
Analysts Offer Predictions for Editas Medicine FY2026 Earnings - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine (EDIT) Unveils Promising Gene Editing Data for B - GuruFocus
Kalkine: Editas Medicine’s In Vivo Gene Editing Progress Unveiled at EHA 2025 with tLNP Approach - Kalkine Media
Breakthrough: New Gene Editing Therapy Achieves 58% Success Rate for Sickle Cell Disease Treatment - Stock Titan
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle - GuruFocus
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hema - GuruFocus
Editas Medicine Reports 58% HBG1/2 Promoter Editing in Non-Human Primates Using High Efficiency tLNP Delivery Method - Nasdaq
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June - The Manila Times
Why Is Editas (EDIT) Up 40% Since Last Earnings Report? - Yahoo Finance
Ameriprise Financial Inc. Has $289,000 Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):